The new pharmaceutical CDMO, launched in 2021, has expanded its sterile manufacturing facility's superstructure
Current state of the superstructure in Visp. Image credit: ten23 health LinkedIn
Ten23 health, a global contract development and manufacturing organization (CDMO) has announced the completion of the superstructure for its new sterile manufacturing facility.
The existing FDA- and Swissmedic-inspected facility of ten23 health’s swissfillon in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in close collaboration with ten23 health’s development centre in Basel.
The new building had been purpose-built for ten23 health, and includes two further sterile manufacturing lines.
In addition to securing renewable energy for the facility, we are investing in photovoltaics across the whole façade
Line 2 will produce large commercial quantities for market supply after regulatory approval of the drug. As a true scaled-up version of the existing filling line 1, the transfer between the lines will be associated with less risk for biopharma customers. The fill line will be based on the latest isolator technology to increase the safety of the drugs for patients. It will focus on complex products, filled into RTU containers including syringes, cartridges and special primary packaging such as used in specific administration devices for subcutaneous delivery.
Line 3 will broaden ten23 health’s offering to also process bulk containers (vials), both in liquid and lyophilized form, with two large-scale freeze-driers, each at 12.5 square meters of shelf-space for clinical and commercial use. ten23 health continues to hire additional personnel to support the new production lines.
A unique feature of the new facility is a photovoltaic façade, covering the complete building exteriors, and is able to provide 45,000 kW per year. ten23 health’s facilities in Basel and Visp already operate with 100% renewable energy, consistent with ten23 health's commitment to helping reduce greenhouse gas emissions and saving the planet.
Hanns-Christian Mahler, CEO of ten23 health, said: “The completion of the initial phase of construction is a major milestone for ten23 health, our customers and their patients, and towards providing a significant amount of capacity for commercial and clinical sterile medicines for patients. In addition to securing renewable energy for the facility, we are investing in photovoltaics across the whole façade. We are excited to continue building ten23 health into a leading sustainable contract development and manufacturing worldwide.”